High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of ischaemic complications during and after coronary interventions and concerns up to 50% of patients undergoing PCI
ObjectivesWe sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed ...
Background Despite outstanding antiplatelet properties of aspirin and clopidogrel, some patients tak...
This study was designed to identify the multivariate effect of clinical risk factors on high on-trea...
High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of ischaemic comp...
BACKGROUND: High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of is...
The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians b...
peer reviewedPR measured before PCI in stable patients undergoing elective PCI who are preloaded wit...
We tested the hypothesis that residual platelet reactivity after clopidogrel correlates with the ext...
Clinical trials have demonstrated the beneficial impact of clopidogrel in preventing major adverse c...
Aspirin and clopidogrel are proven to prevent thromboembolic events during percutaneous coronary int...
BackgroundOptimal platelet reactivity (PR) inhibition is critical to prevent thrombotic events in pr...
Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complicatio...
SummaryBackgroundDual antiplatelet therapy, comprising aspirin and clopidogrel, is recommended in pa...
ObjectivesThe aim of this study was to determine whether low platelet response to the P2Y12 receptor...
ObjectivesThe aim of this prospective trial was to assess whether platelet reactivity to clopidogrel...
ObjectivesWe sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed ...
Background Despite outstanding antiplatelet properties of aspirin and clopidogrel, some patients tak...
This study was designed to identify the multivariate effect of clinical risk factors on high on-trea...
High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of ischaemic comp...
BACKGROUND: High platelet reactivity (HPR) to clopidogrel is associated with an increased risk of is...
The phenomenon of resistance to copidogrel catches the attention of a growing number of clinicians b...
peer reviewedPR measured before PCI in stable patients undergoing elective PCI who are preloaded wit...
We tested the hypothesis that residual platelet reactivity after clopidogrel correlates with the ext...
Clinical trials have demonstrated the beneficial impact of clopidogrel in preventing major adverse c...
Aspirin and clopidogrel are proven to prevent thromboembolic events during percutaneous coronary int...
BackgroundOptimal platelet reactivity (PR) inhibition is critical to prevent thrombotic events in pr...
Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complicatio...
SummaryBackgroundDual antiplatelet therapy, comprising aspirin and clopidogrel, is recommended in pa...
ObjectivesThe aim of this study was to determine whether low platelet response to the P2Y12 receptor...
ObjectivesThe aim of this prospective trial was to assess whether platelet reactivity to clopidogrel...
ObjectivesWe sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed ...
Background Despite outstanding antiplatelet properties of aspirin and clopidogrel, some patients tak...
This study was designed to identify the multivariate effect of clinical risk factors on high on-trea...
DOI
Add to ORKG